Minutes
Cincinnati Children's Hospital
Institutional Biosafety Committee

Meeting Information	
Location:	Virtual
Date and Time:	April 14, 2026 7:30 AM
End Time:	8:47 AM
Chair:	Stephen Waggoner

Attendance	
Name	**Status**
Marcia Espinola	Member Scientist – Non Affiliate
Buddy Goose	Community Member
James Gulick	Member Scientist
Scott Keely	Community Member
Ian Lewkowich	Member Scientist – Vice Chair
Tamara Rausch	Member Scientist - BSO
Debbie Slovut	Community Member
Sherry Thornton	Member Scientist
Stephen Waggoner	Member Scientist - Chair
Patrick Reily	Non-voting Member
Tabitha Dowdy	Biosafety Office
Courtney Roher	Biosafety Office
Quorum	6
Voting	8/9

Minutes from Previous Meeting

03.10.2026 Minutes.docx(0.01)
The meeting minutes from the March 2026 meeting were reviewed by the committee and approved (8 yes; 0 no; 0 abstain).

Expedited Protocols

Study ID	PI	Reviewer
IBC2025-0093	Zhiyuan Chen: MDA	James Gulick
IBC2025-0058	Bhagwat Prasad: M	James Gulick

Expedited protocols approved since the last meeting were presented to the committee.

HRS Amendments

PI:	Damien Reynaud		
Study ID:	Amendment for IBC2024-0081 (April Meeting)		
Title:	Normal and Pathological Hematopoiesis		
Biosafety Items:	AM		
Modification:	Addition of lentivirus		
Primary Reviewer:	Tamara Rausch		
Agents:	Human Derived Blood and Blood Types HL-60 K-562 MOLM-13 U-937 Human Bone Marrow Mononuclear Cells Human CD34+ Cells Human Peripheral Blood Mononuclear Cells Human Primary Umbilical Vein Endothelial Cells Lentivirus		
BSL:	2		
Applicable NIH Guidelines:	Section III-D: *Experiments that Require Institutional Biosafety Committee Approval Before Initiation* Section III-D-3-b: *Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3*		
Motion:	Modifications Required		
Vote:	**Yes:** 8	**No:** 0	**Abstain:** 0
	Recuse:0	**Absent:** 1	

New HRS Protocols

PI:	Jesse Skoch
Study ID:	IBC2026-0028
Title:	Assessment of real-time Optical and Electrophysiological Monitoring Devices in Sheep
Biosafety Items:	AZ
Primary Reviewer:	Marcia Espinola
Secondary Reviewer:	Deborah Slovut
Agents:	Zoonotic risk exposure
BSL:	2
Applicable NIH Guidelines:	N/A
Motion:	Modifications Required

Vote:	**Yes:** 8	**No:** 0	**Abstain:** 0
	Recuse:0	**Absent:** 1	

Protocol Renewals

PI:	Jeff Molkentin
Study ID:	IBC2025-0088
Title:	Cardiovascular and Skeletal Muscle Function
Biosafety Items:	DAVTM
Primary Reviewer:	Stephen Waggoner
Secondary Reviewer:	Brenna Carey
Agents:	293T Cardiovascular Tissue Cardiotoxin (Not Select Agent) AAV Type 9 Adeno-Associated Virus Adenovirus type 5 Lentivirus
BSL:	2
Applicable NIH Guidelines:	Section III-D-3-a: *Experiments involving the use of infectious or defective Risk Group 2 viruses in the presence of a helper system may be conducted at BL2* Section III-D-3-b: *Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3* Section III-D-4: *Experiments Involving Whole Animals* Section III-D-4-a: *Recombinant or synthetic nucleic acid molecules, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study. Animals that contain sequences from viral vectors, which do not lead to transmissible infection either directly or indirectly as a result of complementation or recombination in animals, may be propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study* Section III-D-4-c-(1): *Experiments involving the generation of transgenic rodents that require BL1 containment are*

	described under Section III-E-3, Experiments Involving Transgenic Rodents Section III-D-4-c-(2): *The purchase or transfer of BL1 transgenic rodents is exempt from the NIH Guidelines under Section III-F, Exempt Experiments* Section III-E-1: *Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus* Section III-E-3: *Experiments Involving Transgenic Rodents* Section III-E-3-a: *Experiments involving the breeding of certain BL1 transgenic rodents are exempt under Section III-F, Exempt Experiments*		
Motion:	Modifications Required		
Vote:	**Yes:** 8	**No:** 0	**Abstain:** 0
	Recuse:0	**Absent:** 1	

PI:	Rulang Jiang		
Study ID:	IBC2026-0008		
Title:	Genetic, Genomic, and Developmental Mechanisms of Structural Birth Defects		
Biosafety Items:	DAM		
Primary Reviewer:	Ian Lewkowich		
Secondary Reviewer:	Scott Keely		
Agents:	293T H9 Human iPSC Lines		
BSL:	2		
Applicable NIH Guidelines:	Section III-E: *Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation* Section III-E-3: *Experiments Involving Transgenic Rodents* Section III-E-3-a: *Experiments involving the breeding of certain BL1 transgenic rodents are exempt under Section III-F, Exempt Experiments* Section III-F: *Exempt Experiments* Section III-F-8-C-VII *The purchase or transfer of transgenic rodents, BSL1 only* Section III-F-8-C-VIII: *Generation of BL1 Transgenic Rodents via Breeding*		
Motion:	Modifications Required		
Vote:	**Yes:** 8	**No:** 0	**Abstain:** 0
	Recuse:0	**Absent:** 1	

PI:	David Hildeman
Study ID:	IBC2025-0091
Title:	Molecular Mechanisms of T Cell Apoptosis
Biosafety Items:	DAVPTM
Primary Reviewer:	Sherry Thornton
Secondary Reviewer:	Marcia Espinola
Agents:	Escherichia coli (enteropathogenic) Listeria monocytogenes Human Derived Blood and Blood Types Human Peripheral Blood Mononuclear Cells Diphtheria toxin (Not Select Agent) Staphylococcal enterotoxins Influenza virus type A (Orthomyxoviruses) Lymphocytic choriomeningitis virus (LCM) (neurotropic strains) (Arenaviruses) Murine cytomegalovirus (Herpesvirus) Vaccinia virus Vesicular stomatitis virus
BSL:	2
Applicable NIH Guidelines:	Section III-D: *Experiments that Require Institutional Biosafety Committee Approval Before Initiation* Section III-D-3-a: *Experiments involving the use of infectious or defective Risk Group 2 viruses in the presence of a helper system may be conducted at BL2* Section III-D-3-b: *Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3* Section III-D-4-a: *Recombinant or synthetic nucleic acid molecules, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study. Animals that contain sequences from viral vectors, which do not lead to transmissible infection either directly or indirectly as a result of complementation or recombination in animals, may be propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study*

	Section III-D-4-b: *For experiments involving recombinant or synthetic nucleic acid molecules, or DNA or RNA derived therefrom, involving whole animals, including transgenic animals, and not covered by Section III-D-1 or Section III-D-4-a, the appropriate containment shall be determined by the Institutional Biosafety Committee. Experiments involving gene drive modified animals generated by recombinant or synthetic nucleic acid molecules shall be conducted at a minimum of BL2 or BL2-N* Section III-D-4-c-(2): *The purchase or transfer of BL1 transgenic rodents is exempt from the NIH Guidelines under Section III-F, Exempt Experiments* Section III-E: *Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation* Section III-E-1: *Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus* Section III-E-3*: Experiments Involving Transgenic Rodents*		
Motion:	Modifications Required		
Vote:	**Yes:** 8	**No:** 0	**Abstain:** 0
	Recuse:0	**Absent:** 1	

PI:	Fukun Guo
Study ID:	IBC2026-0009
Title:	Rho GTPases in lymphocyte biology
Biosafety Items:	DAVM
Primary Reviewer:	Tamara Rausch
Secondary Reviewer:	Ian Lewkowich
Agents:	Human Derived Blood and Blood Types 293T HCT-116 Human Peripheral Blood Mononuclear Cells Lentivirus Murine leukemia virus (Retrovirus)
BSL:	2
Applicable NIH Guidelines:	Section III-D: *Experiments that Require Institutional Biosafety Committee Approval Before Initiation* Section III-D-3-b: *Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3*

	Section III-D-4-c-(2): *The purchase or transfer of BL1 transgenic rodents is exempt from the NIH Guidelines under Section III-F, Exempt Experiments* Section III-E *Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation* Section III-E-1: *Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus* Section III-E-3: *Experiments Involving Transgenic Rodents*		
Motion:	Modifications Required		
Vote:	**Yes:** 9	**No:** 0	**Abstain:** 0
	Recuse:0	**Absent:** 0	

PI:	Brian Gebelein		
Study ID:	IBC2026-0006		
Title:	Mechanisms of cell-specific gene regulation		
Biosafety Items:	DI		
Primary Reviewer:	Tamara Rausch		
Secondary Reviewer:	James Gulick		
Agents:	293T H9		
BSL:	2		
Applicable NIH Guidelines:	Section III-E: *Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation* Section III-E-1: *Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus* Section III-E-3: *Experiments Involving Transgenic Rodents* Section III-E-3-a: *Experiments involving the breeding of certain BL1 transgenic rodents are exempt under Section III-F, Exempt Experiments* Section III-F: *Exempt Experiments*		
Motion:	Modifications Required		
Vote:	**Yes:** 9	**No:** 0	**Abstain:** 0
	Recuse:0	**Absent:** 0	

PI:	Christina Gross
Study ID:	IBC2026-0014

Title:	Regulation of intracellular signaling and protein synthesis in epilepsy, autism spectrum disorders and schizophrenia
Biosafety Items:	DAVM
Primary Reviewer:	Stephen Waggoner
Secondary Reviewer:	Sherry Thornton
Agents:	Human Derived Blood and Blood Types 293T Human iPSC Lines Nervous Tissue Adeno-Associated Virus Lentivirus
BSL:	2
Applicable NIH Guidelines:	Section III-D: *Experiments that Require Institutional Biosafety Committee Approval Before Initiation* Section III-D-3: *Experiments Involving the Use of Infectious DNA or RNA Viruses or Defective DNA or RNA Viruses in the Presence of a Helper System in Tissue Culture Systems* Section III-D-3-b: *Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3* Section III-D-4-a: *Recombinant or synthetic nucleic acid molecules, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study. Animals that contain sequences from viral vectors, which do not lead to transmissible infection either directly or indirectly as a result of complementation or recombination in animals, may be propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study* Section III-D-4-b: *For experiments involving recombinant or synthetic nucleic acid molecules, or DNA or RNA derived therefrom, involving whole animals, including transgenic animals, and not covered by Section III-D-1 or Section III-D-4-a, the appropriate containment shall be determined by the Institutional Biosafety Committee. Experiments involving gene drive modified animals generated by recombinant or synthetic nucleic acid molecules shall be conducted at a minimum of BL2 or BL2-N*

	Section III-D-4-c-(2): The purchase or transfer of BL1 transgenic rodents is exempt from the NIH Guidelines under Section III-F, Exempt Experiments Section III-E: *Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation* Section III-E-1: *Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus*		
Motion:	Modifications Required		
Vote:	**Yes:** 9	**No:** 0	**Abstain:** 0
	Recuse:0	**Absent:** 0	

PI:	Rebecca Marsh		
Study ID:	IBC2025-0096		
Title:	Primary Immunodeficiency, Diagnostics, and Cellular Therapy Studies		
Biosafety Items:	VM		
Primary Reviewer:	Ian Lewkowich		
Secondary Reviewer:	Brenna Carey		
Agents:	Human Derived Blood and Blood Types Human urine Human iPSC Lines JURKAT K-562 Mast NK-92 RAJI Human Peripheral Blood Mononuclear Cells Human Liver Tissue Human Spleen Tissue Immune Tissue Integumentary Respiratory Tissue Epstein Barr virus (Herpesvirus)		
BSL:	2		
Applicable NIH Guidelines:	N/A		
Motion:	Modifications Required		
Vote:	**Yes:** 9	**No:** 0	**Abstain:** 0
	Recuse:0	**Absent:** 0	

PI:	Bruce Trapnell		
Study ID:	IBC2026-0001		
Title:	Pathogenesis, Diagnostics, and Therapeutics for Rare Lung Diseases IBC Protocol		
Biosafety Items:	DAVPZM		
Primary Reviewer:	Sherry Thornton		
Secondary Reviewer:	Buddy Goose		
Agents:	Klebsiella pneumoniae Nocardia asteroides Pseudomonas aeruginosa Staphylococcus aureus Streptococcus agalactiae		
BSL:	2		
Applicable NIH Guidelines:	Section III-D *Experiments that Require Institutional Biosafety Committee Approval Before Initiation* Section III-D-1: *Experiments Using Risk Group 2, Risk Group 3, Risk Group 4, or Restricted Agents as Host-Vector Systems* Section III-D-1-a: *Experiments involving the introduction of recombinant or synthetic nucleic acid molecules into Risk Group 2 agents will usually be conducted at Biosafety Level (BL) 2 containment* Section III-D-3-a *Experiments involving the use of infectious or defective Risk Group 2 viruses in the presence of a helper system may be conducted at BL2* Section III-D-3-b *Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3* Section III-E *Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation* Section III-E-1 *Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus* Section III-F Exempt Experiments		
Motion:	Modifications Required		
Vote:	**Yes:** 9	**No:** 0	**Abstain:** 0
	Recuse:0	**Absent:** 0	

Discussion items
None